Insmed Stock Jumps 29% on Encouraging PAH Study Results

• click to rate

  Posted by Two Blokes Jun 11 - Filed in Stock - 7 views
  
  INSM eyes the next steps as TPIP hits all endpoints in the PAH study, setting the stage for late-stage trials and broader potential in lung disease.